Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 5.53% is 83% below its 5-year average of 32.02%, near the low end of its 5-year range (3.30%–434.67%).
As of the fiscal period ended Tuesday, June 30, 2026. 19.62% below its 12-month average of 6.88%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 5.53%.
DEBT TO ASSETS RATIO
5.53%
DEBT TO ASSETS RATIO AVG TTM
6.88%
DEBT TO ASSETS RATIO AVG 3Y
45.76%
DEBT TO ASSETS RATIO AVG 5Y
32.02%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-19.62%
CURRENT VS 3Y AVG
-87.92%
CURRENT VS 5Y AVG
-82.74%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 536 covered companies
CURRENT VS SECTOR MEDIAN
+5426.52%
vs the sector median at left
Ernexa Therapeutics Inc.
Market Cap
$4.67M
Debt to Assets Ratio
5.53%
TTM Avg
6.88%
3Y Avg
45.76%
5Y Avg
32.02%
Market Cap
$4.71M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.55M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.80M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.47M
Debt to Assets Ratio
0.37%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.89M
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | $4.67M | 5.53% | 6.88% | 45.76% | 32.02% |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.71M | 0.02% | N/A | N/A | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | 0.00% | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.80M | 0.00% | N/A | N/A | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.82M | 0.00% | N/A | N/A | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.49M | 0.09% | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.47M | 0.37% | N/A | N/A | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.89M | 0.25% | N/A | N/A | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.18M | 0.00% | N/A | N/A | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.21M | 0.42% | N/A | N/A | N/A |
Debt/Assets
5.5%
Debt/Equity
0.11
Current Ratio
2.01
Interest Coverage
-345.1x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 5.53% |
| 2026-03-31 | 3.69% |
| 2025-12-31 | 8.40% |
| 2025-09-30 | 8.94% |
| 2025-06-30 | 7.82% |
| 2025-03-31 | 56.97% |
| 2024-12-31 | 12.98% |
| 2024-09-30 | 434.67% |
| 2024-06-30 | 105.85% |
| 2024-03-31 | 95.56% |
| 2023-12-31 | 85.16% |
| 2023-09-30 | 78.94% |
| 2023-06-30 | 79.26% |
| 2023-03-31 | 23.35% |
| 2022-12-31 | 18.57% |
| 2022-09-30 | 13.20% |
| 2022-06-30 | 10.49% |
| 2022-03-31 | 3.30% |
| 2021-12-31 | 8.64% |
| 2021-09-30 | 8.20% |
| 2021-06-30 | 5.61% |
| 2021-03-31 | 13.69% |
| 2020-12-31 | 22.45% |
